Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

Lurbinectedin and paclitaxel showed synergism in preclinical studies and have non-completely overlapping toxicity profiles. This phase I trial evaluated a combination of paclitaxel and lurbinectedin with/without bevacizumab in advanced tumors. This trial was divided into Group A, which evaluated wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo, Emiliano, Sessa, Cristiana, Harada, Guilherme, de Miguel, Maria, Kahatt, Carmen, Luepke-Estefan, Xarles Erik, Siguero, Mariano, Fernandez-Teruel, Carlos, Cullell-Young, Martin, Stathis, Anastasios, Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652263/
https://www.ncbi.nlm.nih.gov/pubmed/35947247
http://dx.doi.org/10.1007/s10637-022-01281-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652263/
https://www.ncbi.nlm.nih.gov/pubmed/35947247
http://dx.doi.org/10.1007/s10637-022-01281-z

Ejemplares similares